
Vitamin D plus K2 acts like a drug, not a supplement
An Italian cardiology team's narrative review in IJMS reframes combined vitamin D and K2 as a low-potency pharmacological intervention, arguing that the large neutral RCTs tested the wrong populations and ignored K2 as an essential cofactor.
Supplements
View all →Fitness
View all →
Carbon-plated shoes alter running biomechanics tied to bone stress injury risk
A new study of 23 elite distance runners found that carbon-plated shoes increased rearfoot eversion and lowered cadence compared to neutral trainers. The biomechanical shifts are small but cumulative, and recreational runners face more exposure than elites.

Cold Plunges and Your Brain: What the Science Actually Shows
Cold plunges trigger a measurable surge of noradrenaline and dopamine, but the RCT evidence for long-term mental health benefits is still thin. Two recent studies clarify what the data do and do not support.

How Many Carbs Do Runners Actually Need in 2026
A new review in Endocrine Reviews argues runners only need 10 grams of carbs per hour during long efforts, challenging decades of sports nutrition guidelines. Five experts weigh in on what the evidence actually says and what everyday runners should do.

Best Running Gels, According to Editors and Science
Runner's World editors tested nine energy gels on taste, digestibility, and carbohydrate formulation across months of training. Here is which gels stood out and what the research says about how your body actually absorbs them during long runs.
Cognitive Health
View all →Longevity
View all →
Longevity supplement NOVOS Core improved vascular aging markers in first human trial
A six-month randomized controlled trial at the University of Surrey found NOVOS Core, a 12-ingredient supplement, improved endothelial function, arterial flexibility, and blood pressure in 61 healthy adults over 40. The effect sizes rival those of structured exercise programs, but the study is modest, single-center, and not yet peer-reviewed.

NMN and NR supplements: what the evidence says about NAD precursors and aging
NAD levels drop by roughly half between age 40 and 70, and supplement companies are selling NMN and NR as the solution. The human trials show measurable NAD increases but inconsistent clinical benefits, and the regulatory situation for NMN remains unsettled.

Low-dose oral NMN was safe and moved platelet counts in a phase 1/2 ITP trial
A 25-patient phase 1/2 trial published in Nature Medicine found that low-dose oral NMN was well tolerated in adults with steroid-refractory immune thrombocytopenia, with 20 percent meeting the primary platelet-response endpoint and 52 percent maintaining responses through week 8.

NMN versus NR: what the 2025 evidence actually says
A 2025 Food Frontiers review compares NMN and NR head to head: both raise blood NAD+, but the human trial record falls short of the longevity-extension claims printed on the supplement box.














